Introducing the new RSV vaccine technology into the immunization program for the elderly and those with chronic diseases.

Not only is respiratory syncytial virus (RSV) a common cause of illness in young children, it also poses a serious threat to the elderly and those with underlying health conditions.

Associate Professor Tran Dac Phu, former Director of the Department of Preventive Medicine , was one of the first people to receive the RSV vaccine manufactured by GSK.

The VNVC Vaccination System announced that, in the context of consistently high levels of air pollution and PM2.5 fine dust in many major cities, coupled with the transitional period between rainy and cold seasons leading to an increase in respiratory illnesses, more than 250 VNVC vaccination centers nationwide have officially launched the new technology respiratory syncytial virus (RSV) vaccine, aiming to protect the elderly and those with chronic diseases.

The RSV vaccine, researched and produced by GSK (UK), provides a timely and highly effective solution for proactive and timely prevention of dangerous respiratory diseases in the elderly, those with chronic illnesses, and other high-risk groups.

According to Dr. Bach Thi Chinh, Medical Director of VNVC Vaccination System, the RSV vaccine from GSK (UK) is specifically researched and developed for the elderly, based on a recombinant protein vaccine platform combined with an advanced adjuvant system.

The vaccine uses a specific protein component of the RSV virus, designed in its "most effective" form to help the body generate a maximum immune response, enabling earlier and more accurate virus recognition, thereby providing effective and sustainable disease prevention even in people with weakened health, the elderly, or underlying medical conditions.

“The RSV vaccine has a single-dose schedule for people aged 60 and over, providing maximum and long-lasting protection. Therefore, it can be considered the simplest, most effective, and most economical solution for the elderly against a very strong, dangerous, and common virus like RSV; especially in the context of environmental pollution and many respiratory diseases such as influenza and pneumococcal disease that threaten the health of the elderly,” Dr. Chinh said.

According to data from a large-scale clinical study of over 25,000 people, this vaccine provided 82.6% protection against lower respiratory tract infections caused by RSV in people aged 60 and older, and up to 94.6% in people with at least one underlying condition.

The vaccine has now been approved in nearly 70 countries, with over 10 million doses used worldwide . Many international medical organizations have recommended RSV vaccination for people aged 60 and over or those aged 50-59 who are at high risk.

According to VNA

Source: https://baohaiphong.vn/dua-vaccine-rsv-cong-nghe-moi-vao-tiem-chung-cho-nguoi-cao-tuoi-va-nguoi-co-benh-man-tinh-529727.html